HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services, operating under a "1+2+3+4=1" service system and supplying original PEI products from multiple well-known brands. With over a decade of market experience and manufacturer technology transformation partnerships, HiSiaddi boasts extensive experience addressing product compliance issues. Below is a case of HiSiaddi resolving PEI product compliance challenges.
Please contact HiSiaddi customer service if you require further consultation on PEI product compliance issues.
HiSiaddi built a full compliance closed loop covering REACH/SCIP/RoHS and food contact regulations, successfully securing an annual bulk export order of 86 tons of PEI
The project partner is Med-Swiss AG, a leading European manufacturer of mid-to-high-end medical consumables and precision diagnostic instruments headquartered in Zurich, Switzerland. Its core products include medical endoscopic brackets, disposable high-temperature sterilizable sampling components and insulating parts for in-vitro diagnostic instruments, sold fully across Switzerland, Germany, France, Austria and other EU countries. Product market access complies with five mandatory compliance frameworks: EU REACH Regulation, RoHS2.0 Directive, SCIP notification system, EU 10/2011 food contact material standards and Switzerland’s domestic Chemikalienverordnung chemical control ordinance. All raw materials require testing by EU-accredited third-party laboratories, representing high-end medical end clients with zero-tolerance compliance thresholds, distinct from ordinary low-end civil plastic purchasers.
The enterprise exclusively sourced imported SABIC ULTEM PEI raw materials for years. Faced with extended lead times for overseas original manufacturers, high minimum order thresholds for small batches and year-on-year rising procurement costs, the group’s supply chain launched a domestic PEI import substitution project with a finalized annual framework procurement volume of 86 tons, divided into two categories: medical transparent pure PEI resin (52 tons) and 15% glass fiber reinforced sterilization-grade PEI (34 tons), planned for production in four batches for sea freight to Rotterdam Port, Switzerland for warehousing.
The client independently contacted two domestic PEI modification manufacturers to complete sample testing and initially finalized raw material grades, paying a 30% deposit and scheduling production of the first batch of 22 tons. However, multiple compliance shortcomings emerged shortly before shipment, risking port detention and return of the entire consignment. Manufacturers could only provide basic factory COA quality inspection certificates and simplified Chinese RoHS reports, failing to meet the full set of compliance document requirements for Switzerland’s medical industry, exposing four core compliance pain points:
1. Existing RoHS reports adopted Chinese national GB/T testing standards, inconsistent with EU RoHS2.0 (2011/65/EU) limit indicators and testing methodologies, lacking test data for four phthalate substances, unrecognized by EU customs and client quality control departments;
2. Absence of the latest 2026 REACH-SVHC full screening reports (SVHC updated to 253 substances). Original SDS safety data sheets followed outdated regulatory formats without complying with the new Annex II of EU2020/878, lacking German-language SDS versions and failing EU CLP chemical labeling regulations, unable to complete customs declaration;
3. Trace restricted phthalate substances detected in trace additives of raw materials, exceeding specific migration limits for medical indirect human contact under EU 10/2011 standards;
4. Annual shipment volume exceeding 1 ton mandates mandatory notification to the SCIP database under new ECHA regulations. Domestic manufacturers lack EU local authorized representatives and proficiency in ECHA online reporting rules, unable to complete official filings, leading to direct detention of goods upon port arrival with high detention storage fees and return losses.
Med-Swiss quality control suspended shipment plans for the first batch of goods, with a deadline of 7 working days to supplement full compliance documents and rectify raw material formulas, otherwise the full-year 86-ton procurement order would be canceled and deposit liquidated damages pursued. Domestic two raw material manufacturers only focused on physical production, lacking experience in delivering full compliance for EU medical-grade materials, unable to simultaneously rectify formulas and supplement full international compliance documents. The client fully entrusted HiSiaddi’s technical foreign trade team to handle full-process compliance rectification, document supplementation and SCIP declaration. HiSiaddi deployed dual teams of compliance specialists and polymer material engineers with in-depth expertise in EU plastic import and export regulatory details, relying on CNAS-accredited third-party testing laboratory resources to resolve all compliance challenges itemized in phases.
Domestic manufacturers conducted RoHS testing under Chinese GB/T national standards, only controlling six traditional heavy metals without testing four supplementary phthalate esters (DEHP, BBP, DBP, DIBP) required by EU RoHS2.0. Report measurement units, sampling standards and limit clauses deviated from EU regulations, unrecognized by EU customs. Reports were only issued in Chinese without English versions from EU-accredited laboratories, ineligible for client supply chain access audits.
Original SDS followed outdated 16-chapter formats without disclosing new clauses for nano-fillers and additive components added under 2020 REACH Annex II, with only Chinese versions. EU mandates German-language compliant SDS for shipments to Switzerland and Germany, alongside full screening reports for the latest 253 SVHC substances under REACH. Original reports only covered dozens of routine screening items, omitting numerous newly added high-concern substances and creating hidden risks of SVHC excess notifications.
General lubricant additives incorporated into modified PEI formulas contained trace phthalate derivative components, with room-temperature migration exceeding specific migration limits for EU medical materials. While compliant for industrial-grade products, medical diagnostic components must meet stringent migration standards for indirect human contact, and original general formula additive selections failed medical compliance requirements.
SCIP notification requires EU local importers as declaration subjects. Domestic manufacturers lack EU legal representatives and proficiency in ECHA online system filling logic and material component reporting specifications. Annual export volume exceeding 1 ton with SVHC content exceeding 0.1% without prior filing triggers direct detention of goods upon arrival and administrative fines of 5%–10% of cargo value.
Collaborating with factory formula engineers, HiSiaddi eliminated general lubricants containing phthalate derivatives without altering PEI substrate physical properties or glass fiber addition ratios, replacing them with halogen-free medical-grade silicone high-temperature resistant lubricant systems. Antioxidant additive grades were simultaneously optimized to adopt FDA and EU10 dual-certified imported additives. After formula replacement, small batches were re-sampled and sent to third-party laboratories for full testing of total migration and specific migrants under EU10/2011 standards, with all migration values falling within EU limit thresholds to meet Switzerland’s medical material compliance standards. The full 22 tons of in-production raw materials underwent rework with additive replacement to eliminate fundamental formula compliance defects.
HiSiaddi coordinated ILAC and CNAS dual-qualified international third-party laboratories to conduct full testing of 10 restricted hazardous substances (6 heavy metals + 4 phthalates) under unified IEC62321 EU RoHS testing standards, strictly complying with EU limits: cadmium ≤100ppm, other heavy metals ≤1000ppm, four phthalates all ≤1000ppm. Qualified English original test reports with attached laboratory qualification schedules were issued, directly usable for EU customs clearance and client medical device supply chain access reviews.
1. Conduct full-component screening of two PEI grades against the latest 253-item ECHA SVHC list updated in 2026, covering PEI resin monomers, glass fiber and all modified additives and colorants through full raw material traceability testing. Issue Chinese-English bilingual REACH-SVHC compliance reports proving all component SVHC content below the 0.1% control threshold, exempting mandatory high-concern substance notification obligations.
2. Compliance specialists re-compiled standard 16-chapter SDS in accordance with REACH Annex II (EU2020/878) new regulations, detailing risks of melt thermal decomposition, safety guidelines for medical sterilization environments and waste disposal specifications. EU certified translation agencies were commissioned to produce compliant German SDS versions to meet dual-country customs documentation requirements for Switzerland and Germany. Full SDS packages include UFI hazard codes complying with EU CLP chemical labeling regulations.
Leveraging long-term cooperative Swiss local compliance agencies, HiSiaddi designated Med-Swiss’s Swiss entity as the EU import declaration subject, sorting full PEI component chemical names, CAS numbers, component proportions, annual import tonnage and product application scenarios, itemizing entry into the ECHA-SCIP online reporting system to complete official filing for two PEI grades and obtain official SCIP filing receipt numbers, fully supplementing mandatory EU filing vouchers and eliminating compliance gaps from absent local declarants.
Targeting Switzerland’s exclusive Chemikalienverordnung control regulations, HiSiaddi sorted raw material component lists and compliance summary forms, issuing local compliance statements via cooperative Swiss law firms to adapt to additional random inspection requirements of Swiss customs, completing a full chain of localized compliance documents.
The full set of compliance rectification, testing, document compilation and SCIP filing was completed within 6 working days, delivering a complete multi-language compliance document package to the client within the specified deadline: pre- and post-formula rectification comparison reports, EU10 medical migration test reports, updated RoHS2.0 reports, 253-item SVHC-REACH reports, German/English bilingual SDS documents, SCIP filing receipts and Swiss chemical compliance statements. Med-Swiss quality control fully approved all materials, lifting the shipment suspension order. The first batch of 22 tons of PEI was loaded and shipped on schedule, smoothly clearing customs at Rotterdam Port without any random inspection objections from customs authorities. Raw materials were put into production lines in Switzerland for injection molding of medical components, with all performance and hygiene indicators passing inspection after repeated 134℃ ethylene oxide high-temperature sterilization, successfully entering Switzerland’s domestic medical device supply chain.
The subsequent three batches totaling 64 tons of raw materials were produced and shipped in installments under identical compliance standards, with 100% fulfillment of the full-year 86-ton domestic PEI order. Comprehensive procurement costs decreased by 29% compared with original imported SABIC raw materials. In the year following project implementation, Med-Swiss added procurement demand for high-purity PEI dedicated to medical implant components with an annual volume increase of 41 tons, fully adopting HiSiaddi’s standardized compliance control model.
The vast majority of domestic PEI modification manufacturers focus on physical property R&D of materials yet generally lack research capabilities on segmented EU regulatory frameworks, with insufficient awareness of dynamic updates to the REACH-SVHC list, supplementary RoHS2.0 clauses, SCIP notification, national localized chemical regulations and special compliance requirements for medical materials, only capable of providing domestic-format test documents. Mid-to-high-end European medical end clients are bound by stringent EU environmental and chemical regulations, with raw material compliance serving as a rigid market access threshold. Non-compliant raw material formulas or supporting documents will easily trigger severe losses including port detention, return of goods, fines or cancellation of full-year framework orders.
Traditional ordinary foreign trade only handles supply source connection, customs declaration and shipment, unable to proactively control full-chain risks including formula compliance, international testing and overseas regulatory filing. Supported by dual reserves of compliance and material technology, HiSiaddi closed-loop resolved all compliance challenges across five dimensions: raw material source formula rectification, third-party compliance testing, multi-language document compilation, EU official filing and localized regulatory adaptation. It assisted domestic manufacturers in optimizing product formulas to meet overseas high-end market standards while helping overseas high-end clients evade EU customs and supply chain compliance risks. This case confirms that full-chain compliance supporting services constitute an indispensable core competitiveness for domestic high-end PEI to break import monopolies in overseas high-end medical device markets and sustain long-term presence across mid-to-high-end European markets, as well as the key value distinguishing technology-driven foreign trade from traditional intermediaries.
Please contact HiSiaddi customer service if you require further consultation on PEI product compliance issues.
+86-13120989737 
info@hisiaddi.com 
English
